Your browser doesn't support javascript.
loading
Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases.
Cobb, J; Cule, E; Moncrieffe, H; Hinks, A; Ursu, S; Patrick, F; Kassoumeri, L; Flynn, E; Bulatovic, M; Wulffraat, N; van Zelst, B; de Jonge, R; Bohm, M; Dolezalova, P; Hirani, S; Newman, S; Whitworth, P; Southwood, T R; De Iorio, M; Wedderburn, L R; Thomson, W.
Afiliación
  • Cobb J; 1] Arthritis Research UK Centre for Genetics and Genomics, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK [2] NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manche
  • Cule E; Department of Epidemiology and Biostatistics, Imperial College London, London, UK.
  • Moncrieffe H; Rheumatology Unit, UCL Institute of Child Health, London, UK.
  • Hinks A; Arthritis Research UK Centre for Genetics and Genomics, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
  • Ursu S; Rheumatology Unit, UCL Institute of Child Health, London, UK.
  • Patrick F; Rheumatology Unit, UCL Institute of Child Health, London, UK.
  • Kassoumeri L; Rheumatology Unit, UCL Institute of Child Health, London, UK.
  • Flynn E; Arthritis Research UK Centre for Genetics and Genomics, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
  • Bulatovic M; Department of Paediatric Immunology, University Medical Centre Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands.
  • Wulffraat N; Department of Paediatric Immunology, University Medical Centre Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands.
  • van Zelst B; Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • de Jonge R; Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • Bohm M; First Faculty of Medicine and General Faculty Hospital, Charles University in Prague, Praha, Czech Republic.
  • Dolezalova P; First Faculty of Medicine and General Faculty Hospital, Charles University in Prague, Praha, Czech Republic.
  • Hirani S; Centre for Health Services Research, School of Health Sciences, City University London, London, UK.
  • Newman S; Centre for Health Services Research, School of Health Sciences, City University London, London, UK.
  • Whitworth P; Institute of Child Health, Birmingham Children's Hospital, Birmingham, UK.
  • Southwood TR; Institute of Child Health, Birmingham Children's Hospital, Birmingham, UK.
  • De Iorio M; Department of Statistical Sciences, University College London, London, UK.
  • Wedderburn LR; 1] Rheumatology Unit, UCL Institute of Child Health, London, UK [2] Arthritis Research UK Centre for Adolescent Rheumatology, UCL Institute of Child Health, London, UK.
  • Thomson W; 1] Arthritis Research UK Centre for Genetics and Genomics, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK [2] NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manche
Pharmacogenomics J ; 14(4): 356-64, 2014 Aug.
Article en En | MEDLINE | ID: mdl-24709693
Clinical response to methotrexate (MTX) treatment for children with juvenile idiopathic arthritis (JIA) displays considerable heterogeneity. Currently, there are no reliable predictors to identify non-responders: earlier identification could lead to a targeted treatment. We genotyped 759 JIA cases from the UK, the Netherlands and Czech Republic. Clinical variables were measured at baseline and 6 months after start of the treatment. In Phase I analysis, samples were analysed for the association with MTX response using ordinal regression of ACR-pedi categories and linear regression of change in clinical variables, and identified 31 genetic regions (P<0.001). Phase II analysis increased SNP density in the most strongly associated regions, identifying 14 regions (P<1 × 10(-5)): three contain genes of particular biological interest (ZMIZ1, TGIF1 and CFTR). These data suggest a role for novel pathways in MTX response and further investigations within associated regions will help to reach our goal of predicting response to MTX in JIA.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Artritis Juvenil / Metotrexato Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Pharmacogenomics J Asunto de la revista: BIOLOGIA MOLECULAR / FARMACOLOGIA Año: 2014 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Artritis Juvenil / Metotrexato Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Pharmacogenomics J Asunto de la revista: BIOLOGIA MOLECULAR / FARMACOLOGIA Año: 2014 Tipo del documento: Article